Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of “Hold” from Brokerages

Oxford Immunotec Global PLC (NASDAQ:OXFD) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $18.75.

OXFD has been the subject of a number of recent analyst reports. BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global and gave the company a “buy” rating in a report on Tuesday, October 31st. Cowen reiterated a “buy” rating and set a $19.00 price target on shares of Oxford Immunotec Global in a report on Thursday, September 28th. Robert W. Baird reissued a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th.

Shares of Oxford Immunotec Global (OXFD) opened at $11.59 on Thursday. Oxford Immunotec Global has a 1-year low of $10.81 and a 1-year high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38. The company has a market cap of $297.34, a price-to-earnings ratio of -5.77 and a beta of -0.09.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, October 31st. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. Oxford Immunotec Global had a negative net margin of 45.74% and a negative return on equity of 38.42%. equities analysts anticipate that Oxford Immunotec Global will post -2.16 earnings per share for the current fiscal year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now directly owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.11% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA grew its position in shares of Oxford Immunotec Global by 7.8% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 501,307 shares of the company’s stock worth $8,422,000 after buying an additional 36,187 shares during the period. Perceptive Advisors LLC grew its position in shares of Oxford Immunotec Global by 955.1% in the 3rd quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock worth $7,818,000 after buying an additional 421,250 shares during the period. Alyeska Investment Group L.P. grew its position in shares of Oxford Immunotec Global by 44.0% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock worth $22,773,000 after buying an additional 413,904 shares during the period. RTW Investments LP grew its position in shares of Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after buying an additional 185,453 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $2,726,000. 89.30% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of “Hold” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/25/oxford-immunotec-global-plc-oxfd-receives-average-recommendation-of-hold-from-brokerages.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply